Catalog No.
Product Name
Application
Product Information
Citations
- Ombrabulin hydrochloride is a derivative of CA-4 phosphate, which is known to exhibit antivascular effects through selective disruption of the tubulin cytoskeleton of endothelial cells.
-
tubulin polymerization inhibitor
Soblidotin (Auristatin PE) is a novel synthetic Dolastatin 10 derivative and inhibitor of tubulin polymerization. -
β-tubulin polymerization inhibitor
Valecobulin (CKD516) is a valine prodrug of (S516) and a vascular disrupting agent (VDA). Valecobulin is a potent β-tubulin polymerization inhibitor with marked antitumor activity against murine and human solid tumors. -
tubulin inhibitor
altobulin (HTI-286; SPA-110) is an analogue of Hemiasterlin; potent tubulin inhibitor; ADCs cytotoxin. -
cytotoxic tubulin modifier
Auristatin F is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAF analog and cytotoxin in Antibody-drug conjugates. Auristatin F inhibits cell division by blocking the polymerisation of tubulin. -
cytotoxic tubulin modifier
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates. Auristatin E inhibits cell division by blocking the polymerisation of tubulin. - Dolastatin 10 (DLS 10) is a potent antimitotic peptide, isolated from the marine mollusk Dolabela auricularia, that inhibits tubulin polymerization.
-
inhibitor of tubulin polymerization
4-Oxo-4-HPR is an inhibitor of tubulin polymerization, inducing marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. It is also a fenretinide metabolite. -
Ras Activator
Methylophiopogonanone B is a homoisoflavonoid that serves as a Ras activator. Isolated from the root of Ophiopogon japonicus, it exhibits potent antioxidant properties. This compound enhances GTP-Rho levels and activates the Rho signaling pathway, thereby inducing morphological changes in cells, such as actin cytoskeletal reorganization, dendrite retraction, and stress fiber formation. It is a valuable reagent for research into cellular signaling and structural dynamics. -
Tubulin Inhibitor
Demecolcine is a potent tubulin inhibitor that effectively disrupts microtubule polymerization, exhibiting an IC50 value of 2.4 μM. By binding to tubulin dimers, Demecolcine exerts anti-mitotic effects, hindering cellular division. This compound is primarily utilized in research related to inflammatory disorders and various cancer pathways, making it valuable for studies focused on cell cycle regulation and targeted therapies. -
Microtubule Acetylation Inhibitor
GM-90257 is a potent microtubule acetylation inhibitor that directly binds to α-tubulin. By preventing the recruitment of α-tubulin acetyltransferase 1 (αTAT1) to the K40 residue, GM-90257 disrupts microtubule dynamics, leading to apoptotic cell death. It downregulates Bcl-2 and activates key apoptotic pathways, including JNK and PARP. This compound demonstrates significant anticancer activity in breast cancer models, making it a valuable tool for research in cancer therapeutics and microtubule biology. -
Microtubule Inhibitor
MPT0B214 is a potent microtubule inhibitor that targets the colchicine binding site of tubulin, effectively preventing tubulin polymerization. This compound induces apoptosis via a mitochondrial/caspase 9 dependent pathway and exhibits significant cytotoxic effects across a range of human tumor cell lines. MPT0B214 is suitable for applications in cancer research, allowing for further exploration of microtubule dynamics and therapeutic strategies. -
Anti-Tubulin Agent
DPQZ is an anti-tubulin agent that disrupts microtubule dynamics, leading to inhibition of cell separation and inducing cell cycle arrest at the G2/M phase. Additionally, DPQZ triggers caspase-dependent apoptosis in HSC-3 cells through the inhibition of Ras/Raf signaling and the activation of MAP kinase pathways. This compound is relevant for research applications in studying oral cancer biology and therapeutic strategies. -
Tubulin Polymerization Inhibitor
Trilexium is a potent tubulin polymerization inhibitor that effectively disrupts microtubule integrity. This compound promotes the expression of p21 protein and triggers apoptotic pathways, demonstrating significant anti-cancer activities across various cell lines. Trilexium holds promise for research applications focused on cancer biology and novel therapeutic strategies targeting microtubule dynamics. -
Tubulin Inhibitor
Tubulin polymerization-IN-68 is a potent tubulin inhibitor that disrupts tubulin polymerization, thereby destabilizing the microtubule network within cells. This compound induces apoptosis by upregulating PARP-1 and caspase-3 expression, showcasing significant anticancer properties. Tubulin polymerization-IN-68 demonstrates effective inhibition of HepG2 cells with an IC50 of 93 nM and substantially reduces the growth of HepG2 xenograft tumors in nude mice when administered orally, making it a valuable tool for cancer research. -
Microtubule-stabilizing Agent
Simotaxel is a microtubule-stabilizing agent that acts as an orally active derivative of the taxane class. It binds to β-tubulin, promoting tubulin polymerization with an EC₅₀ of 0.9 μM, while inhibiting tubulin depolymerization and causing cell cycle arrest in the G₂-M phase. Additionally, Simotaxel disrupts mitotic spindle formation and activates the caspase-dependent apoptotic pathway. This compound is particularly relevant for research into Paclitaxel- and Docetaxel-resistant solid tumors, demonstrating inhibitory effects on cell lines sensitive to these treatments. -
Tubulin Inhibitor
STK899704 is a potent tubulin polymerization inhibitor that demonstrates broad-spectrum antitumor activity across various cancer cell lines, with IC50 values between 0.2 and 1.0 μM. By disrupting mitotic spindle formation, STK899704 induces G2/M phase cell cycle arrest and decreases cell migration in HT29 cells through the FAK-MEK-ERK signaling axis, leading to reduced expression and activity of MMP-2 and MMP-9. This compound activates caspases 3, 7, 8, and 9, resulting in PARP cleavage and subsequent apoptosis, alongside triggering cellular senescence via the p53 pathway. STK899704 is applicable in research focusing on skin cancer, lung cancer, colon cancer, and other malignancies. -
Microtubule/Tubulin Inhibitor
Maytansine is a highly potent microtubule-targeting agent that disrupts microtubule dynamics, leading to mitotic arrest and apoptosis in tumor cells. It exerts cytotoxic effects at subnanomolar concentrations and serves as the cytotoxic payload component in several antibody–drug conjugates (ADCs) used for targeted cancer therapy. - Estramustine is an antineoplastic agent that exerts antimitotic activity by depolymerizing microtubules through binding to tubulin 1. It inhibits mitosis in DU 145 prostate cancer cells with an IC50 of approximately 16 μM and induces mitotic arrest in prostate tumor xenograft models, making it a valuable compound for prostate cancer research and therapy.
-
Microtubule/Tubulin Inhibitor
EAPB 02303 is a microtubule-disrupting agent that inhibits microtubule dynamics, leading to mitotic arrest and impaired spindle assembly. This disruption induces apoptosis and contributes to its antitumor activity. EAPB 02303 also demonstrates potent synergistic effects with Paclitaxel at lower concentrations, enhancing its potential in combination cancer therapies. -
Apoptosis activator
Sulforaphene, a natural compound isolated from radish seeds, exhibits an ED₅₀ of approximately 2 × 10⁻⁴ M against velvetleaf seedlings. It promotes apoptosis and inhibits migration in cancer cells by suppressing signaling pathways including EGFR, phosphorylated ERK1/2 (p-ERK1/2), and NF-κB. -
CBSI inhibitor
MY-673 is a colchicine binding site inhibitor (CBSI) that disrupts microtubule dynamics by inhibiting tubulin polymerization. In addition to its antimitotic effects, MY-673 suppresses the ERK signaling pathway, which leads to modulation of SMAD4 protein expression within the TGF-β/SMAD signaling axis. These combined actions result in potent inhibition of cancer cell proliferation and migration, and the induction of apoptosis, both in vitro and in vivo. MY-673 holds promise as a therapeutic candidate for targeting cancers driven by aberrant microtubule dynamics and dysregulated TGF-β/ERK signaling. -
HDAC6 inhibitor
T-518 is an orally active, selective histone deacetylase 6 (HDAC6) inhibitor with an IC₅₀ of 36 nM for human HDAC6. It is capable of crossing the blood–brain barrier, making it suitable for central nervous system applications. T-518 is particularly useful in tauopathy research, where HDAC6 inhibition may modulate tau pathology and neurodegenerative processes. -
Tubulin/AKT1 Inhibitor
Tubulin/AKT1-IN-1 is an inhibitor of tubulin polymerization and AKT pathway activation. This compound demonstrates significant inhibition of proliferation and metastasis in H1975 cells, along with a modest induction of apoptosis. Tubulin/AKT1-IN-1 is particularly relevant for research in non-small cell lung cancer (NSCLC), providing a valuable tool for studying therapeutic strategies against this malignancy. -
Tubulin Inhibitor
Tubulin-IN-55 is a potent tubulin inhibitor that disrupts the PI3K/Akt signaling pathway in cancer cells. This compound exhibits broad-spectrum anti-proliferative effects against various tumor cell lines, including HeLa, HCT116, 4T1, A549, H1299, and MDA-MB231. Tubulin-IN-55 induces G2/M phase arrest and promotes apoptosis, while also inhibiting tumor cell migration and invasion. In vivo studies demonstrate significant antitumor efficacy in orthotopic autologous transplantation models, making Tubulin-IN-55 a valuable tool for cancer research. -
Microtubule Depolymerizing Agent
Naphthazarin is a microtubule depolymerizing agent that exhibits significant biological activity in various research applications. It has been shown to improve motor function and decrease neuroinflammation in mouse models of Parkinson's disease. Additionally, Naphthazarin induces apoptosis, autophagy, and cell cycle arrest in tumor cells. Its ability to trigger erythrocyte apoptosis further underscores its potential utility in studies of tumors and neurodegenerative diseases. -
Tubulin/CDC5L Inhibitor
Tubulin/CDC5L-IN-1 is a dual inhibitor targeting both tubulin and CDC5L. It inhibits cancer cell proliferation and induces G2/M phase arrest, facilitating apoptosis and reactive oxygen species (ROS) production in affected cells. Additionally, Tubulin/CDC5L-IN-1 demonstrates antiangiogenic properties, making it a valuable tool for cancer research, particularly in studies related to colon carcinoma. -
Microtubule Inhibitor
Microtubule Inhibitor 2 acts as a selective microtubule disruptor, inducing cell death via ferroptosis. This compound demonstrates significant antitumor activity, making it a valuable tool for cancer research. Its oral bioavailability enhances its utility in in vivo studies, facilitating investigations into the mechanisms underlying microtubule-targeted therapies. -
Microtubule Inhibitor
Microtubule Inhibitor 8 (MP-HJ-1b) targets microtubule dynamics, acting as a potent disruptor of microtubule processing. This compound initiates cell death through the ferroptosis pathway and exhibits significant anti-tumor activity. It serves as an essential tool for research in cancer biology and therapeutic development focused on targeting microtubules. -
Tubulin Inhibitor
Tubulin Inhibitor 30 is a potent tubulin polymerization inhibitor, exhibiting an IC50 of 0.52 μM. This compound disrupts microtubule dynamics, leading to the induction of ferroptosis in various cell types. It serves as a valuable tool for research on cancer biology and therapeutic applications targeting the cytoskeletal network. - Combretastatin A4 is an antitumor, antiangiogenic and antimetastatic agent, in vitro and in vivo. Combretastatin A4 is a microtubule-targeting agent that binds β-tubulin with Kd of 0.4 μM.
-
microtubule depolymerizing agent
Ansamitocin P-3 is a maytansine analog which displays potent cytotoxicity against the human solid tumor cell lines A-549 and HT-29. -
microtubule dynamics inhibitor
Vinblastine sulfate inhibits microtubule formation and suppresses nAChR activity with IC50 of 8.9 μM in a cell-free assay, used to treat certain kinds of cancer. - Monomethyl auristatin F (MMAF) is a synthetic antineoplastic agent. It is part of some experimental anti-cancer antibody-drug conjugates such as vorsetuzumab mafodotin and SGN-CD19A.
- Vinorelbine Tartrate is a semi-synthetic vinca alkaloid, and inhibits mitosis through interaction with tubulin.
